Patients with Very High Risk of Cardiovascular Adverse Events during Carfilzomib Therapy: Prevention and Management of Events in a Single Center Experience

SIMPLE SUMMARY: The use of carfilzomib in multiple myeloma is burdened by cardiovascular toxicity. Currently, the risk stratification of cardiovascular adverse events appears well established, while the prognosis of patients classified as being at high risk or experiencing adverse events is uncertai...

Descripción completa

Detalles Bibliográficos
Autores principales: Mingrone, Giulia, Astarita, Anna, Colomba, Anna, Catarinella, Cinzia, Cesareo, Marco, Airale, Lorenzo, Paladino, Arianna, Leone, Dario, Vallelonga, Fabrizio, Bringhen, Sara, Gay, Francesca, Veglio, Franco, Milan, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953901/
https://www.ncbi.nlm.nih.gov/pubmed/36831492
http://dx.doi.org/10.3390/cancers15041149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953901/
https://www.ncbi.nlm.nih.gov/pubmed/36831492
http://dx.doi.org/10.3390/cancers15041149

Ejemplares similares